Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Tremfya® (guselkumab) – New indication
March 20, 2025 - Johnson and Johnson announced the FDA approval of Tremfya (guselkumab), for the treatment of adult patients with moderately to severely active Crohn’s disease (CD).
